Health Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CAMS, Tianjin
Alternate hemibody irradiation + HD chemotherapy treats hematological malignancy
March 22nd, 2005
Alternate hemibody irradiation plus high-dose chemotherapy treats hematological malignancies. "The objective of this study was to evaluate the clinical outcome of the treatment of hematologic malignancies with alternate hemibody irradiation (AHBI) combined with high-dose chemotherapy. "Seventeen patients with hematologic malignancies were treated with AHBI combined with high-dose chemotherapy. Following high-dose chemotherapy, upper hemibody irradiation (UHBI) and lower hemibody irradiation (LHBI) were given sequentially in a dose of 6 to 9 Gy," scientists in China report. "UHBI was given 14 days (range, 12-22 days) after...
Source: Health Risk Factor Week (2005-03-22)
|
